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Abstract: Chronic mild stress (CMS) affects the hippocampal structure and function in the 
rat.  S100B,  a  calcium-binding  protein  secreted  by  astrocytes,  has  been  shown  to  be 
increased  in  serum  of  patients  with  depression  and  associated  with  good  therapeutic 
response  and  clinical  outcome.  This  work  aimed  to  study  the  impact  of  CMS  and 
fluoxetine on depressive-like behaviors in rats, as well as the concomitant expression of the 
astroglial protein S100B and of its receptor RAGE (receptor for advanced glycation end 
products)  in  the  hippocampus  and  Cerebrospinal  fluid  of  the  same  group  of  animals. 
S100B and sRAGE (circulating soluble form of RAGE) were measured in CSF by ELISA, 
and S100B and RAGE were measured in hippocampal slices by Western blot. Our study 
has  demonstrated  that  stress  and  depression  decrease  S100B  and  RAGE/SRAGE 
expression  and  antidepressant  treatment  reverses  or  blocks  these  effects.  This  result 
suggested  that  S100B/RAGE  interactions  may  be  involved  in  the  development  and 
maintenance  of  depression  and  may  play  an  important  role  in  the  mechanism  of 
antidepressants’ therapeutic action. 
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1. Introduction 
Recently, the role of glia cells in the pathobiology of depression is becoming apparent, highlighted 
recently by the postmortem finding of a reduced number of glial cell in patients with major depressive 
disorders  [1].  The  gila-derived  neurotrophic  marker  S100B,  a  calcium-binding  protein  produced 
mainly by astrocytes, has been shown to be increased in the serum of patients with a melanchlolic 
subtype of major depression. It has been demonstrated that increased S100B serum concentrations in 
major depression were associated with good therapeutic response and clinical outcome [2,3], which 
suggests a role of S100B in the modulation of the course of depression. There is some evidence that 
rats  exposed  to  chronic  restraint  stress  have  a  decrease  of  neurogenesis  in  the  dentate  gyrus  of 
hippocampus, which is accompanied by a non-significant  increase in  the percentage of cells  with 
astrocytic  phenotype  identified  by  S100B  immunostaining  [4].  Previous  reports  showing  that 
fluoxetine treatment increases the content of S100B in the hippocampus of aged mice [5], and that 
hippocampal astrocyte cultures and hippocampal slices exposed to fluoxetine increase their S100B 
secretion by a mechanism independent of serotonin [6]. Recently, the receptor for advanced glycation 
end products (RAGE) has been suggested to be the putative receptor for S100B [7]. RAGE plays a 
crucial role in several disease processes, such as diabetes, inflammation, and neurodegeneration [8,9], 
Multiple roles of RAGE in neuronal differentiation and neurite outgrowth have been reported [9].   
S100B is unique in that it can engage RAGE in neurons at low and high concentrations with trophic 
and toxic effects. S100B/RAGE interactions might have important consequences during development 
and  in  tissue  homeostasis  as  well  as  in  inflammatory,  degenerative  and  tumor  processes  [7,8]. 
Soluble RAGE  (sRAGE),  lacking  the  transmembrane  and  signaling  domains,  is  generated  by 
alternative splicing (endogenous secretory RAGE/esRAGE) or by matrix-metalloproteinase induced 
ectodomain shedding [10].   
We  purpose  that  S100B/RAGE  (sRAGE)  interactions  might  participate  in  the  pathobiology  of 
depression and could be a target for the action of antidepressant drugs. So, the primary aim of the 
present  study  was  to  investigate  the  changes  in  the  expression  of  S100B  and  RAGE/SRAGE  in 
hippocampus and CSF of rats exposed to chronic mild stress, and the effect of a four week treatment 
with  the  antidepressant  fluoxetine.  We  used  quantitative  Western  immunoblotting  and  ELISA  to 
investigate  the  content  of  S100B  and  RAGE/SRAGE  in  the  hippocampus  and  CSF  of  rats. 
Furthermore, we used open field tests and sucrose preference tests to explore the effects of CMS on 
activity  and  anhedonia  of  rats  and  correlated  these  findings  with  protein  changes  observed  in 
the hippocampus. 
2. Results and Discussion 
2.1. Effects on Sucrose Consumption, Body Weight and Open-Field Test 
Sucrose consumption and body weight Figure 1 (a) and (b), crossing (c), number of rears (d), and 
the urine or excrement frequency (e), were measured twice during the experimental period. As shown, 
no differences were found among four groups of rats before CMS. The three weeks of chronic stress 
induced a marked decrease in the sucrose consumption, body weight, crossings and rears of open field 
activity, but  an increase in the urine or excrement frequency in the stressed rats compared to  the Int. J. Mol. Sci. 2010, 11                         
 
5312 
non-stressed  group.  [F  (3,36)  =  7.605,  p  <  0.001;  F  (3,36)  = 4.132,  p  <  0.01;  F (3,36) =  80.42, 
p < 0.001; F (3,39) = 98.502, p < 0.001; F (3,36) = 69.369, p < 0.001]. 
Figure 1. Effects on sucrose consumption, body weight and open field test. * p < 0.001 vs. 
control,
 # p < 0.01 vs. CMS (one-way ANOVA followed by Bonferroni test). Results are 
expressed as mean ±  S.D. (a) 24 h 1% sucrose consumption of rats before and after CMS; 
(b) Body weight of rats before and after CMS; (c) Crossing of rats before and after CMS; 
(d) Rears of rats before and after CMS; (e) The urine or excrement frequency of rats before 
and after CMS. 
 
(a) 
 
(b) Int. J. Mol. Sci. 2010, 11                         
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Figure 1. Cont. 
 
(c) 
 
(d) 
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2.2. Effects of CMS and Fluoxetine Treatment on Expression of S100B and sRAGE in the CSF 
CSF S100B and sRAGE expression in control rats (Con) and rats subjected to chronic mild stress 
(CMS), chronic mild stress + fluoxetine (CMS + Flu) or fluoxetine (Flu) (Figure 2a and 2b). CMS 
significantly  downregulated  S100B  and  sRAGE  levels,  an  effect  prevented  by  the 
concomitant administration of Fluoxetine (CMS + Flu). Figure 2a and 2b [S100B one-way ANOVA, F 
(3,36) = 5.471, p = 0.003, SRAGE one-way ANOVA, F (3,36) = 6.033, p < 0.02, followed by the 
Bonferroni test, p < 0.05]. 
Figure  2.  Effects  of  CMS,  CMS  +  Flu  and  Flu  on  the  levels  of  S100B  and  sRAGE 
in the CSF of rats. (* p < 0.05 vs. control, 
# p < 0.05 vs. CMS). Results are expressed as 
mean ±  S.D. (a) Effects of CMS, CMS + Flu and Flu on the Levels of S100B in the CSF of 
rats; (b) Effects of CMS, CMS + Flu and Flu on the levels of SRAGE in the CSF of rats. 
(a) 
 
(b) 
 
2.3. Effects of CMS and Fluoxetine Treatment on Expression of S100B and RAGE in the Hippocampus 
Photomicrograph illustrates an example of S100B and RAGE protein analysis using Western blot 
(Figure 3a). Graphic representation of S100B and RAGE protein expression in control rats (Con) and 
rats subjected to chronic mild stress (CMS), chronic mild stress + fluoxetine (CMS + Flu) or fluoxetine 
(Flu). CMS significantly downregulated S100B and RAGE levels (p < 0.05), an effect prevented by 
the concomitant administration of Fluoxetine (CMS + Flu) (p < 0.05). Administration of Flu alone 
(under  stress-free  conditions)  shows  a  significant  increase  in  S100B  and  RAGE  levels  (p < 0.05) 
(Figure 3b and 3c).   
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Figure 3. Representative Western blot bands and densitometric analyses of the bands of 
S100B  and  RAGE  in  the  hippocampus.  Results  are  expressed  as  mean  ±   S.D. 
(a) Representative  Western  blot  bands  and  densitometric  analyses  of  the  bands  for: 
(A) S100B, (B) RAGE, (C) Actin and (D) CMS, Control, CMS + FLU, FLU; (b) Effect of 
CMS and FLU on hippocampus S100B levels (* p < 0.05 vs. control, 
# p < 0.05 vs. CMS, 
followed by the Bonferroni test); (c) Effect of CMS and FLU on hippocampus RAGE 
levels (* p < 0.05 vs. control, 
# p < 0.05 vs. CMS, followed by the Bonferroni test).   
(a) 
 
(b) 
 
(c) 
 
2.4. Disscusions 
We used CMS  as  it has  been shown to  produce behavioral  changes  that  are similar to  human 
depression  and  considered  to  be  a  valid  and  useful  experimental  model  of  depression  [11,12]. 
Concurrently, the rats were treated with fluoxetine which was reported to have the ability to reverse 
stress-induced changes. Our present study reveals that chronic stress and fluoxetine treatment exert 
opposing effects on the regulation S100B expression in CSF and hippocampus of rats. S100B levels 
are decreased in the CSF and hippocampus of rats after chronic unpredictable stress when compared 
with normal controls. The findings may be paralleled with the recent work by Sakatani et al. who 
reported  S100B  is  released  in  a  neural  activity  dependent  manner,  possibly  through  activation  of 
mGluR3 and some neural activity are influenced in S100B knockout mice [13,14].This result is also 
consistent with previous studies which show that S100B expression in serum was increased rather than 
decreased after CMS and chronic antidepressant treatment reversed CMS induced increased S100B 
expression in serum [2,3]. This report indicates that central and peripheral S100B changes do not occur 
in  parallel  and  that  plasma  S100B  levels  can’t  be  a  surrogate  marker  for  CNS  and  hippocampal 
S100B levels. Int. J. Mol. Sci. 2010, 11                         
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In fact, it is difficult to reconcile the reduction of plasmatic S100B caused by antidepressants in 
humans  with  the  observation  that  fluoxetine  treatment  enhances  the  content  of  S100B  in  the 
hippocampus of aged mice [5], and that it promotes the secretion of S100B by hippocampal astrocyte 
cultures and hippocampal slices through a mechanism independent of serotonin [15]. A novel theory of 
depression  has  been  formulated  that  proposes  a  deficiency  in  adult  brain  neurogenesis  as  the 
pathobiological  basis of  depression [16–18]. Correlated with  this,  there is  extensive evidence that 
demonstrates an involvement of S100B in neurogenesis. In serotonergic neurons, S100B acts as a 
trophic factor and a neurite outgrowth and differentiation promoter and even appears to neutralize 
neurotoxic challenges [18]. Most importantly, it stimulates the outgrowth of neuritis and promotes the 
survival of neurons during development. S100B has been shown to be released by astrocytes to the 
extracellular  space  and  to  affect  astrocytes  in  an  autocrine  manner  and  neurons  in  a  paracrine 
manner [19–21].  Once  released,  effects  of  S100B  on  target  cells  depend  on  its  concentration.  At 
nanomolar  concentrations,  S100B  is  trophic  in  that  the  protein  stimulates  neurite  outgrowth  [14], 
enhances  survival  of  neurons  during  development,  and,  after  injury,  prevents  motor  neuron 
degeneration in newborn rats after sciatic nerve section [12,18].   
Our present study also reveals that chronic stress and fluoxetine treatment exert opposing effects on 
the regulation of RAGE expression in the hippocampus of rats. RAGE levels are decreased in the 
hippocampus of rats after chronic unpredictable stress when compared with normal controls.   
It has been suggested that S100B interacts with the RAGE on the cell surface and RAGE has been 
proposed as a signal transducing receptor for both trophic and toxic effects of S100B [8,9]. Treatment 
with  S100B  significantly  elevated  RAGE-mRNA  levels  in  the  rat  hippocampal  neurons  cultures, 
lending  support  to  the  notion  that  S100B  acts  as  a  direct  RAGE  ligand  in  primary  neurons  [9]. 
At the low  levels  normally  found  in  the  brain  extracellular  space,  S100B  acts  as  a  neurotrophic 
factor protecting  neurons  against  noxious  stimuli  and,  also,  binding  of  S100B  to  RAGE  in 
neurons has been shown  to  result  in  the  up-regulation  of  the  antiapoptotic  factor,  Bcl-2,  in  a 
Ras-MEK-ERK1/2-NF-kB  dependent  manner  [7],  which  strongly  supports  the  notion  that  S100B 
might protect neurons against noxious stimuli and promote neuronal repair during the very early phase 
following brain insults and might contribute to neuronal differentiation .Ultimately, such actions of 
S100B  and  RAGE  could  increase  adult  neurogenesis.  RAGE  may  also  participate  in  neuronal 
differentiation and neurite outgrowth. RAGE has been previously shown to mediate neurite outgrowth 
on amphoterin coated matrices [7]. Furthermore, studies have shown that RAGE mediated neurite 
outgrowth can be abolished by deleting the cytoplasmic domain of RAGE [7,9]. Taken together, our 
findings  support  the  possibility  that  decreased  expression  of  S100B  and  RAGE  in  hippocampus 
contributes to the deficiency in neurogenesis that underlies chronic mild stress.   
Malberg et al. show that chronic fluoxetine could be effective in increasing S100B levels in rat 
hippocampus [22]. Our result is in keeping with a previous study; moreover, Malberg et al. treated 
unstressed rats with fluoxetine while we treated stressed rats with fluoxetine. It has been reported that 
chronic antidepressant treatment increases cell proliferation and granule cell survival and is able to 
reverse the stress-induced decrease of hippocampal neurogenesis [11,23]. Thus, the observed S100B 
and RAGE changes following 21 days fluoxetine treatment, strongly suggest that chronic fluoxetine 
could be effective in recovering the decrease of S100B and RAGE levels induced by stressors in rat   
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hippocampus, and chronic fluoxetine administration has the potential to affect neuronal and synaptic 
remodeling via changes in S100B/RAGE dynamics. 
In this study a decrease, rather than an increase, in CSF s100B and sRAGE levels was observed 
after CMS in  the rats.  The stressed  animals  that  were chronically treated with  fluoxetine showed 
increased expression of CSF s100B and sRAGE, Soluble RAGE (sRAGE), lacking the transmembrane 
and signaling domains, is generated by alternative splicing (endogenous secretory RAGE/sRAGE) or 
by matrix-metalloproteinase induced ectodomain shedding [10]. In human subjects, studies suggest 
that the absolute levels of soluble RAGE may correlate with chronic disease states and their severity, 
and that soluble RAGE levels may be mutable consequent to therapeutic interventions [10]. A number 
of studies have suggested that administration of soluble RAGE is protective against oxidative stress 
and neuronal death [10,24], and low levels of sRAGE have been indicated as a possible new marker of 
low-grade inflammation [25]. Given the beneficial role of sRAGE in metabolic and inflammatory 
diseases, we hypothesized a similar effect in depression, possibly related to a self-limiting regulatory 
mechanism contributing to a normalization of S100B levels. Thus, it is plausible that soluble RAGE 
may represent a therapy for disease states in which the ligands of RAGE accumulate. Many questions 
remain to be addressed, such as whether soluble RAGE display identical affinity for RAGE ligands 
and whether sRAGE levels in CSF or plasma could benefit or biomark depression. No doubt, as the 
literature is abounding with studies examining soluble RAGE in the human subject in homeostasis and 
disease, the answers to these questions are soon to be revealed. 
Although  stress  resilient  animals  are  often  found  [26,27],  we  did  not  find  any  of  the  stressed 
resilient animals in this study. As in previous studies [28,29], this study confirmed that CMS caused 
reduction in sucrose consumption, motor and exploratory activities. Furthermore, the stressed animals 
treated with fluoxetine showed a significant increase in sucrose consumption, motor and exploratory 
activities. These behavioral changes were accompanied with decreased S100B and RAGE/sRAGE 
levels,  and  increased  S100B  and  RAGE/sRAGE  levels,  respectively.  These  findings  could  be 
indicative of hippocampal and CSF S100B and RAGE/sRAGE changes which might in turn contribute 
to  the  behavioral  changes.  However,  although  these  findings  showed  a  correlation  between 
S100B/RAGE interactions  and behavioral  changes  in rats,  it should be underlined that we cannot 
conclude whether S100B/RAGE interactions play a causal or only a correlative role with the observed 
changes. A behavioral study found some behavioral phenotypes with RAGE KO mice, and this study 
suggested  deletion  of  RAGE  causes  hyperactivity  and  increased  sensitivity  to  auditory  stimuli  in 
mice [30]. The relationship between changes in behavioral phenotype and S100B/RAGE interactions 
needs to be further investigated. 
The results of this study can be interpreted as follows: It can be assumed that a decrease in levels of 
S100B and RAGE/sRAGE in hippocampus and CSF of chronic stress rats indicates a neuroprotective 
activity  that  is  evidence  that  certain  mechanisms  of  neuronal  plasticity  and  neurogenesis  may  be 
functionally impaired in major depression. Treatment with Fluoxetine can prevent the impaired process 
of  neuronal  plasticity  and  neurogenesis  through  actions  of  S100B  and  RAGE.  S100B/RAGE 
interactions involved in development and maintenance of depression and may play an important role in 
the mechanism of the antidepressants therapeutic action.   Int. J. Mol. Sci. 2010, 11                         
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3. Experimental Section 
3.1. Animals 
Forty adult male Sprague-Dawley rats from the Wuhan University’s Animal Center (5–7 weeks old, 
weighing 250–300 g) were housed with ad lib access to food and water, and maintained on a 12-h 
light/dark cycle (lights on at 7:00 a.m.), at 22 ° C with low humidity. All animal experiments were 
carried  out  in  accordance  with  the  National  Institute  of  Health  Guide  for  the  Care  and  Use  of 
Laboratory Animals (NIH publication 8023, revised 1996) and with the approval of the local Animal 
Use Committee.   
After one week of habituation, rats were randomly divided into four groups of 10 animals each. The 
group I (Con) received saline (1 mL/kg), group II (FLU) received Fluoxetine (10 mg/kg) + saline 
(1 mL/kg), group III (CMS) received CMS + saline (1 mL/kg) and group IV (CMS + FLU) received 
CMS + Fluoxetine (10 mg/kg) + saline (1 mL/kg). Fluoxetine (10 mg/kg) (Sigma, St. Louis, MO, U.S.) 
were intraperitoneally administered with a volume of 10 mL/kg repeatedly. The repeated treatment was 
performed once a day. For the CMS + FLU and FLU rats, the administration of antidepressants was 
from day 1 to day 21. Doses of 10 mg/kg of fluoxetine were chosen because, at such a level, fluoxetine 
has been reported to show antidepressant action in previous work [28,31]. The weight of rats and 
consumption of saccharose was monitored during the periods of stress as an index. Open field test was 
used  to  observe  the  behavior  of  rats  on  the  day  before  stimulation  and  on  the  22nd  day 
during experiment. 
3.2. The CMS Model and Behavior Test 
The  CMS  model  of  depression  is  accepted  as  a  valuable  method  for  evaluating  antidepressant 
effects in animals. In this model, animals subject to various stressors such as unpredictable order and 
stimulating  conditions  in  the  natural  environment,  show  many  behavioral,  biochemical  and 
physiological impairments, which parallel the symptoms of depression in human. In the present study, 
the CMS procedure consisted of a variety of unpredictable mild stressors including repeated periods 
of 45°  cage tilt; two 2-h periods of separated housing; one overnight period of limited access to food 
(12-h separation of rats from their chow by direct touching of rat by glass clapboard with holes of 
3 mm diameter, yet without any reduction in the actual daily food ration); one period of continuous 
overnight  illumination;  and  one  overnight  period  in  a  soiled  cage  (50  mL  of  water/L  of  sawdust 
bedding). Animals were also placed on a reversed light/dark cycle from Friday evening to Monday 
morning. These stressors were scheduled over a one-week period and repeated throughout the 3-week 
experiment [31,32]. In contrast to previous procedures in rats, nociceptive stressors were excluded, and 
only environment and social disturbances were applied. The non-stressed control animals were housed 
in normal conditions without any influences. The injections of fluoxetine or saline were applied just 
after the stressing procedures. 
All rats were tested for sucrose consumption and given 1% (w/v) sucrose solution in water for 24 h 
in place of their regular drinking water in their home cages, following 24 h period of water deprivation 
on the 1st and the 22nd day, respectively. The bottles were weighed prior to being given to the rats and 
at the conclusion of the test (7:00 a.m. the next morning). On the 1st and 22nd day, the weight of rats Int. J. Mol. Sci. 2010, 11                         
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was recorded and rats  were submitted to the  open-field test. The open-field was a 50 ×  25  ×  50 
chamber made of brown polywood with frontal glass wall. The floor of the open-field was divided into 
12 equal squares by black lines. Animals were placed on the left rear quadrant and left to explore the 
arena. Animals were observed for 3 min to record the number of rears (animal on hind limbs), crossing 
(grid boxes entered) and the urine or excrement frequency. 
3.3. Tissue Isolation, Western Blot and ELISA 
After the behavior experiment, CSF samples (used for ELISA determinations) were obtained by 
magna  cistern  puncture  and  hippocampus  (used  for  quantitative  Western  immunoblotting 
determinations) were isolated through the stereo toxic atlas of the rat brain and then were snap-frozen. 
For  determination  of  S100B  and  RAGE  protein  level,  protein  extracts  were  obtained  from  the 
hippocampus  of  brain  according  to  the  following  protocol.  Each  assay  sample  consisted  of  the 
hippocampus from one rat. Each sample was weighed and homogenized in 1.5 mL of sample buffer 
(0.01 M Tris-HCl buffer (pH 7.6) containing 0.25 M sucrose, 0.1 M NaCl, 1 mM EDTA, and 1 mM 
phenylmethylsulfonylfluoride) at 4 ° C. Supernatant, after 12,000 rpm centrifugation for 10 min, was 
used for Western blotting. Protein concentration was determined according to the method of Bradford. 
Samples  were  dissolved  with  equal  volume  of  loading  buffer  (0.1  M  Tris-HCl  buffer  (pH 6.8) 
containing  0.2  M  DTT,  4%  SDS,  20%  glycerol  and  0.1%  bromophenol  blue),  separated  on 
10% SDS-PAGE and then electrotransferred at 100 V to Immun-Blot PVDF membrane for 1 h at 4 ° C. 
Membranes were blocked in Tris-Buffered Saline Tween-20 (TBST) containing 5% non-fat dried milk 
overnight at 4 ° C before incubation for 2 h at room temperature. Blots were then incubated with either 
one  of  the  following:  Rabbit  anti-S100B  polyclonal  antibody  (1:1000,  Santa  Cruz),  or  rabbit 
anti-RAGE polyclonal antibody (1:1000, Santa Cruz) for 1.5 h at room temperature. The blot was 
washed  several  times  with  TBST  and  then  incubated  with  the  secondary  antibody, 
peroxidase-conjugated anti-rabbit IgG dilution (1:10,000, Santa Cruz). Signal detection was performed 
with  an  enhanced  chemiluminescence  kit.  The  relative  changes  of  the  intensity  of  each 
immunoreactive band were captured and analyzed using GeneSnap Image Analysis Software (Syngene, 
U.K.). CSF S100B was measured by immunoluminometry (E0567rS100B ELISA kit, ELAabscience, 
Wuhan,  China)  according  to  the  manufacturer’s  instructions.  CSF  sRAGE  was  determined  by 
sandwich  enzyme-linked  immunosorbentassay  (SK0011203sRAGE  ELISA  kit,  Yunhan  Biology, 
Shanghai, China) according to the manufacturer’s instructions. 
3.4. Statistical Analysis 
Results are expressed as mean ±  S.D and analyzed by SPSS 11.0. Repeated measures analysis of 
variance (ANOVA) was used for  post-hoc analysis  for differences  between  groups.  p  < 0.05  was 
considered statistically significant. 
4. Conclusions 
This  study  is  the  first  to  demonstrate  that  S100B/RAGE  interactions  may  be  involved  in  the 
development and maintenance of depression and that it may play an important role in the mechanism 
of antidepressants’ therapeutic action.   Int. J. Mol. Sci. 2010, 11                         
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